Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Income from Continuing Operations (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Income from Continuing Operations for 7 consecutive years, with 21749000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 56.27% to 21749000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 147516000.0 through Dec 2025, up 29.86% year-over-year, with the annual reading at 147516000.0 for FY2025, 29.86% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 21749000.0 at Pliant Therapeutics, up from 26301000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 21749000.0 in Q4 2025, with the low at 57763000.0 in Q3 2024.
  • Average Income from Continuing Operations over 5 years is 36987000.0, with a median of 36304000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 307.24% in 2021, then surged 56.27% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 24531000.0 in 2021, then plummeted by 42.92% to 35060000.0 in 2022, then decreased by 17.25% to 41109000.0 in 2023, then dropped by 20.98% to 49732000.0 in 2024, then soared by 56.27% to 21749000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 21749000.0, 26301000.0, and 43300000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.